Matrixyl 3000 3-10%
Topical matrikine peptide complex evaluated in dermatological research for skin firming, extracellular matrix synthesis, and photoprotection.
Mechanism
Stimulates dermal fibroblasts to upregulate collagen and extracellular matrix synthesis while downregulating interleukin-6 mediated inflammatory degradation.
Dosing
Topical application protocols typically start with a 3% concentration serum applied once daily as a thin layer to clean skin.
Reconstitution
Matrixyl 3000 is formulated into topical water-based serums or emulsions at a 3% to 10% target concentration without requiring bacteriostatic water reconstitution.
Storage
Store the peptide formulation in an airtight, light-blocking container in a cool, dark environment or refrigerated to prevent oxidative and photolytic degradation.
Mix & measure Matrixyl 3000 3-10%
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Matrixyl 3000 3-10%
Vial strength → BAC water → target dose
Total doses in vial: —
U-100 syringe: 100 units = 1 mL
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Patch Test (48 h) | Trace amount once | 0.05 mL |
| Weeks 1–2 (Intro) | 3-10% serum once daily (PM) | ~0.25 mL (pea-sized) |
| Weeks 3–8 (Build) | 3-10% serum 1–2× daily | ~0.25 mL (pea-sized) |
| Weeks 8–12+ (Maintenance) | 3-10% serum 1–2× daily | ~0.25 mL (pea-sized) |
Reconstitution Steps
- 1
Measure the designated aqueous serum, gel, or cosmetic base in a sterile laboratory vessel.
- 2
Incorporate Matrixyl 3000 at the target final concentration, commonly between 3% and 10% by volume.
- 3
Gently blend the formulation until homogeneous, taking care to avoid intense mechanical shear or high heat.
- 4
Verify product clarity, ensure adequate preservative integration for aqueous solutions, and dispense into opaque containers.
Supplies Needed
Peptide Vial
Contains the Matrixyl 3000 concentrated raw material or topical stock.
Insulin Syringes (U-100)
Not utilized for topical application protocols; pipettes or droppers are used instead.
Bacteriostatic Water
Not required for topical formulation preparation.
Alcohol Swabs
Used to sanitize laboratory preparation surfaces, glassware, and container necks.
Why researchers study it
Dermal collagen and extracellular matrix synthesis
Periorbital and forehead fine line mitigation
Modulation of pro-inflammatory cytokines such as IL-6
Cutaneous elasticity and architectural firmness
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Matrixyl 3000 is an extensively referenced cosmeceutical matrikine complex composed of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7. Designed specifically for topical dermatological investigation, the dual-peptide formulation mimics degraded extracellular matrix fragments to stimulate regenerative cellular pathways within dermal fibroblasts without inducing physical tissue injury. In cutaneous models, the palmitoylated lipid chains facilitate passive absorption through the hydrophobic stratum corneum barrier. Once delivered into dermal layers, the signaling peptides act synergistically to modulate structural protein synthesis and downregulate localized cytokine-driven matrix breakdown, serving as a primary target for topical anti-aging and tissue remodeling investigations.
References
- 1.Lintner K, Peschard O, Int J Cosmet Sci, 2000 — biologically active peptides moving from laboratory curiosity to functional skin-care ingredients, including the palmitoylated matrikine rationale
- 2.Errante F et al., Front Chem, 2020 — review of cosmeceutical peptides (signal, carrier and neurotransmitter-inhibitor classes) and the evidence supporting their claimed cosmetic activity
- 3.Katayama K et al., J Biol Chem, 1993 — the original report that a pentapeptide (KTTKS) from type I procollagen promotes extracellular-matrix production by fibroblasts
- 4.Schagen SK, Cosmetics, 2017 — review of topical peptide treatments and anti-aging results, covering signal peptides such as the Matrixyl family and honest limits on the evidence
- 5.Robinson LR et al., Int J Cosmet Sci, 2005 — double-blind, placebo-controlled facial study showing topical palmitoyl pentapeptide (Pal-KTTKS) improved the appearance of photoaged skin over ~12 weeks
- 6.Pickart L, Margolina A, Int J Mol Sci, 2018 — regenerative and protective actions of the GHK-Cu peptide, the copper-complexed relative of the GHK motif in palmitoyl tripeptide-1
- 7.Pai VV et al., Indian J Dermatol Venereol Leprol, 2017 — review of topical peptides as cosmeceuticals, emphasizing modest effect sizes and the primacy of sunscreen and retinoids in skin aging
- 8.Choi YL et al., Biomol Ther, 2014 — dermal stability and in-vitro skin permeation of KTTKS and palmitoyl-KTTKS, characterizing how palmitoylation improves peptide penetration
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.